Dr. Michael Mina
, Chief Science Officer at eMed Digital Healthcare
Dr. Mina is the Chief Science Officer of eMed. Prior to eMed he was a professor of Epidemiology and of Immunology & Infectious Diseases at the Harvard T.H. Chan School of Public Health. He was also a professor in the Department of Pathology at Harvard Medical School and associate medical director of molecular virology at Brigham and Women’s Hospital. Dr. Mina is one of the leading global experts regarding the COVID-19 pandemic, particularly around vaccines and testing. During the COVID pandemic his research shifted towards how testing can help limit spread of the SARS-CoV-2 virus. Prior to coming to eMed, his research created much of the theory around how both PCR and rapid tests should be used in the context of a pandemic of a fast moving respiratory virus like SARS-CoV-2. In addition, he was instrumental in setting up some of the largest PCR testing laboratories in the nation, at the Broad Institute of MIT and Harvard, and quickly grew to prominence as a leading international authority on rapid antigen testing in the pandemic. Throughput the COVID-19 pandemic he has advised both White House administrations, the US Congress and Senate, many US states, corporations and numerous international governments about their testing and vaccine programs. Dr. Mina went to Dartmouth College for his undergraduate studies where he earned a bachelor’s degree in engineering and public health. He earned both his M.D. and Ph.D. degrees at Emory University. Dr. Mina is the recipient of numerous national and institutional awards for his research, including a recipient of the prestigious NIH Director’s Early Independence Award. He was identified by the Economist Magazine as one of 8 Global Progress makers for his global health research and not-for-profit work helping bring clean water to rural areas of the world. He is on the board of directors or the scientific or medical advisory boards of numerous public and private companies.